Medical-grade skincare company, Senté, announced they've closed on a strategic partnership and equity financing and the appointment of new executive board positions including Zubin Meshginpoosh as Chief Executive Officer and President.
This milestone positions the company to accelerate growth and expand the reach of its patented Heparan Sulfate Analog (HSA) and Dermatan Sulfate and Chondroitin Sulfate (DECO) technologies, which are at the core of Senté's clinically proven formulations and unique products.
Related: Senté Announces the Appointment of New CFO
"I am thrilled to see Zubin in his new role as CEO and excited to help him and the company reach the next level of its growth and development. Senté is and always has been a pioneer in regenerative skincare through biomimetic evidence-based science. We want to see more individuals benefiting from our breakthrough products and this financing and the expansion of our leadership team will ensure this growth," the company said in a statement.
As part of this next phase, the Senté Board of Directors has also appointed co-founder Kleanthis G. Xanthopoulos, Ph.D., as Executive Chairman of the Board. Over the course of his career, Xanthopoulos has founded five three to successful public listings on NASDAQ, and structured numerous strategic partnerships with leading global pharmaceutical and biotechnology organizations.
